The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are described herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant I DH proteins including, but not limited to, cell-proliferation disorders, such as cancer.<；sp />；<；sp />；<；sp />；<；sp />；<；sp />； L'invention concerne également des compositions contenant un composé de formule (I) et l'utilisation de ces composés dans l'inhibition de protéines IDH mutantes ayant une activité néomorphe. L'invention concerne en outre l'utilisation d'un composé de formule (I) dans le traitement de maladies ou de troubles associés à ces protéines IDH mutante, comprenant, sans s'y limiter, des troubles de la prolifération cellulaire, comme le cancer.
